Results 161 to 170 of about 1,183 (178)

Cell-Free DNA Fragmentomics: The Novel Promising Biomarker

International Journal of Molecular Sciences, 2023
Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and active release mechanisms, which carry the genetic and epigenetic information of its origin tissues. However, cfDNA is the mixture of various cell fragments, and the efficient enrichment of cfDNA fragments with diagnostic value remains a great challenge for ...
Qinyu Ge, Min Pan, Yunfei Bai
exaly   +4 more sources

Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer [PDF]

International Journal of Molecular Sciences, 2022
Identifying novel circulating biomarkers predictive of response and informative about the mechanisms of resistance, is the new challenge for breast cancer (BC) management.
Ugo de Giorgi, Michela Palleschi, Caterina Gianni   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Science, 2021
Enhancing liquid biopsies Liquid biopsies, analyses of cell-free DNA that circulates in the blood, can be used in prenatal testing, oncology, and to monitor organ transplant recipients. Lo et al. review the nongenetic information that can be gleaned from analyses of cell-free DNA, which offers additional ...
Y. M. Dennis Lo, Diana S. C. Han, Peiyong Jiang, Rossa W. K. Chiu   +3 more
openaire   +2 more sources

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology, 2023
The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment.
K T, Helzer, M N, Sharifi, J M, Sperger, Y, Shi, M, Annala, M L, Bootsma, S R, Reese, A, Taylor, K R, Kaufmann, H K, Krause, J L, Schehr, N, Sethakorn, D, Kosoff, C, Kyriakopoulos, M E, Burkard, N R, Rydzewski, M, Yu, P M, Harari, M, Bassetti, G, Blitzer, J, Floberg, M, Sjöström, D A, Quigley, S M, Dehm, A J, Armstrong, H, Beltran, R R, McKay, F Y, Feng, R, O'Regan, K B, Wisinski, H, Emamekhoo, A W, Wyatt, J M, Lang, S G, Zhao   +33 more
openaire   +2 more sources

Fragmentomics of proteins and natural oligopeptides

Biophysics, 2008
The term fragmentomics is grounded and defined. Theoretical structure-function analysis of all possible fragments of a protein molecule was performed under the concept of fragmentomics to determine the regions that could be potential sources of regulatory oligopeptides.
openaire   +3 more sources

Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer

Cancer Research
Abstract Colorectal cancer is frequently diagnosed in advanced stages, highlighting the need for developing approaches for early detection. Liquid biopsy using cell-free DNA (cfDNA) fragmentomics is a promising approach, but the clinical application is hindered by complexity and cost.
Yuepeng Cao, Nannan Wang, Xuxiaochen Wu, Wanxiangfu Tang, Hua Bao, Chengshuai Si, Peng Shao, Dongzheng Li, Xin Zhou, Dongqin Zhu, Shanshan Yang, Fufeng Wang, Guoqing Su, Ke Wang, Qifan Wang, Yao Zhang, Qiangcheng Wang, Dongsheng Yu, Qian Jiang, Jun Bao, Liu Yang   +20 more
openaire   +2 more sources

cfDNA fragmentomics for preeclampsia prediction

To investigate whether cfDNA fragmentomic features have the potential to predict early-onset or late-onset PE, we performed WGS of plasma cfDNA (>10X final read depth) from pregnant women with PE (n=109 for early-onset PE, n=333 for late-onset PE) and sampling-gestation-matched healthy controls (n=476).
openaire   +1 more source

Integration of cfDNA fragmentomics for early biliary tract cancer detection.

Journal of Clinical Oncology
4131 Background: Biliary Tract Cancer (BTC) is a highly aggressive malignancy with poor survival outcomes, primarily due to the lack of effective early detection methods and late-stage diagnoses.
Jiwen Wang, Xiaojian Ni, Yuxuan Zheng, Qingxin Xie, Hua Bao, Kun Fan, Dongqin Zhu, Hairong Bao, Ruowei Yang, Chunyan Wang, Bohao Zheng, Shuang Chang, Xiuxiu Xu, Haimeng Tang, Xiaoling Ni, Tao Suo, Xue Wu, Sheng Shen, Han Liu, Houbao Liu   +19 more
openaire   +1 more source

Cell-free DNA fragmentomics and methylomics for thymic epithelial tumors.

Journal of Clinical Oncology
8118 Background: Development of circulating cell-free (cf) DNA assays for cancer detection and monitoring is an area of active research. Limited data are available on the utility of cfDNA for thymic epithelial tumors (TETs).
Michael Daniels, Elizabeth R. Francis, Ling Su, Xiaolin Wu, Elsa Bahiru, Shannon Swift, Christine Feierabend, Susan Sansone, Laercio Lopes DaSilva, Eva Szabo, Chen Zhao, Meredith Jo McAdams, Arun Rajan   +12 more
openaire   +1 more source